Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
3.1 (USD) • At close March 12, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 351.367 | 48.633 | 0 | 0 |
| Cost of Revenue
| 0 | 70.09 | 0.26 | 0.029 | 0.019 | 0.017 | 0.017 |
| Gross Profit
| 0 | -70.09 | -0.26 | 351.338 | 48.614 | -0.017 | -0.017 |
| Gross Profit Ratio
| 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Reseach & Development Expenses
| 144.101 | 132.843 | 81.936 | 167.205 | 38.023 | 10.17 | 6.675 |
| General & Administrative Expenses
| 48.849 | 49.919 | 48.714 | 45.785 | 21.64 | 4.438 | 2.802 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 48.849 | 49.919 | 48.714 | 45.785 | 21.64 | 4.438 | 2.802 |
| Other Expenses
| 0 | -88.69 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 192.95 | 94.072 | 130.65 | 212.99 | 59.663 | 14.608 | 9.477 |
| Operating Income
| -192.95 | -164.162 | -130.65 | 138.377 | -11.03 | -14.608 | -9.477 |
| Operating Income Ratio
| 0 | 0 | 0 | 0.394 | -0.227 | 0 | 0 |
| Total Other Income Expenses Net
| 25.49 | 29.224 | 11.151 | 0.213 | 0.083 | 0.574 | 0.413 |
| Income Before Tax
| -167.46 | -134.938 | -119.499 | 138.59 | -10.947 | -14.034 | -9.064 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0.394 | -0.225 | 0 | 0 |
| Income Tax Expense
| -0.925 | 1.018 | -3.59 | 17.4 | -0.083 | -0.574 | 0.413 |
| Net Income
| -168.385 | -135.956 | -115.909 | 121.19 | -10.864 | -13.46 | -9.064 |
| Net Income Ratio
| 0 | 0 | 0 | 0.345 | -0.223 | 0 | 0 |
| EPS
| -2 | -1.63 | -1.39 | 1.46 | -0.13 | -0.16 | -0.19 |
| EPS Diluted
| -2 | -1.63 | -1.39 | 1.37 | -0.13 | -0.16 | -0.19 |
| EBITDA
| -192.95 | -119.593 | -110.844 | 138.406 | -11.011 | -14.591 | -9.46 |
| EBITDA Ratio
| 0 | 0 | 0 | 0.394 | -0.226 | 0 | 0 |